

LEVEL III

ASKLEPIOS Course

INTRODUCTION TO HYBRID IMAGING IN ONCOLOGY

August 31 - September 1, 2017
Vienna/Austria



This ASKLEPIOS course is implemented with great support and partnership of ESHI (European Society of Hybrid Medical Imaging).

Education in partnership.

LEVEL III

ASKLEPIOS Course

INTRODUCTION TO HYBRID IMAGING IN ONCOLOGY

August 31 – September 1, 2017
Vienna/Austria

Course information

This course is aimed at last-year residents, general radiologists, nuclear medicine physicians and oncologists who want to update their knowledge on new applications and state-of-the-art hybrid medical imaging of cancer. No previous practical experience of the subject is required. The expert faculty comprises nuclear medicine physicians and radiologists who will provide a series of lectures describing optimal imaging pathways for oncological diagnosis, follow-up and response assessment. Lectures will be followed by interactive workshops, presented jointly by faculty specialists.

Learning objectives

- to learn the principles of hybrid medical imaging
- to learn the key clinical questions at different points in the patient's journey
- to understand the indications, limitations and comparative merits of each part in hybrid medical imaging in a wide range of oncologic conditions and how it relates to other modalities
- to appreciate the complementary roles of structural and functional/molecular imaging in cancer management
- to understand hybrid medical imaging pathways for a range of different tumour types including non-small cell lung cancer, lymphoma, head and neck, prostate and gynaecological cancer
- to understand how information derived from imaging guides patient selection for treatment and supports individualised treatment planning



Programme

INTRODUCTION TO HYBRID IMAGING IN ONCOLOGY

August 31 – September 1, 2017
Vienna/Austria

Thursday, August 31, 2017

- 12:00–13:00 Registration
- 13:00–13:15 Welcome and introduction
- 13:15–14:15 **Introduction to hybrid medical imaging, radiotracers and physics**
K. Riklund, Umeå/SE; T. Beyer, Vienna/AT
- 14:15–15:15 **Lung cancer**
H. Prosch, Vienna/AT; F. Giesel, Heidelberg/DE
- 15:15–15:45 Coffee break
- 15:45–17:00 **Workshops**
(K. Riklund, T. Beyer, H. Prosch, F. Giesel)

Host Organisers



K. Riklund
Umeå/SE



C. Herold
Vienna/AT

Friday, September 1, 2017

- 09:00–10:00 **Lymphoma**
A. Vanzulli, Milan/IT; T. Hany, Zurich/CH
- 10:00–11:00 **Colorectal cancer**
R. Beets-Tan, Amsterdam/NL; M. Stokkel, Amsterdam/NL
- 11:00–11:20 Coffee break
- 11:20–12:30 **Workshops**
(A. Vanzulli, T. Hany, R. Beets-Tan, M. Stokkel)
- 12:30–13:30 Lunch break
- 13:30–14:30 **Prostate cancer**
H.-P. Schlemmer, Heidelberg/DE; M. Hartenbach, Vienna/AT
- 14:30–15:30 **Gynaecologic cancer**
R. Forstner, Salzburg/AT; A. Rockall, London/UK
- 15:30–15:50 Coffee break
- 15:50–17:00 **Workshops**
(H.-P. Schlemmer, M. Hartenbach, R. Forstner, A. Rockall)
- 17:00–17:30 Summary and round of discussion
- 17:30 Certificate of attendance

Venue

Venue to be confirmed

Registration fee

ESR members in training
Early fee EUR 200; Late fee EUR 250

Non-members in training
Early fee EUR 300; Late fee EUR 350

ESR members
Early fee EUR 300; Late fee EUR 350

Non-members
Early fee EUR 400; Late fee EUR 450

(Early fee until eight weeks prior to the course)
(Late fee after eight weeks prior to the course)

Registration fees are inclusive 10% VAT.

LEVEL III

Learning Objectives

INTRODUCTION TO HYBRID IMAGING IN ONCOLOGY

August 31 – September 1, 2017
Vienna/Austria

Introduction to hybrid medical imaging, radiotracers and physics

K. Riklund, Umeå/SE

- to get familiar with the combination of structural and molecular imaging
- to understand the physiological or biochemical background of the most commonly used tracers for PET imaging
- to get an overview of the indications for hybrid imaging

Introduction to hybrid medical imaging, radiotracers and physics

T. Beyer, Vienna/AT

- to understand what is hybrid imaging
- to discuss why is hybrid imaging better than standalone imaging
- to learn what is a radiotracer and why it is not a contrast agent
- to discuss where hybrid imaging (SPECT/CT, PET/CT, PET/MR) will take us

Lung cancer

H. Prosch, Vienna/AT

- to understand the importance of a diligent staging in lung cancer patients
- to appreciate the strengths and weaknesses of CT and MRI in lung cancer staging
- to become familiar with the most important pitfalls in lung cancer staging

Lymphoma

A. Vanzulli, Milan/IT

- to explain the role of cross-sectional radiologic imaging in initial staging of lymphomas
- to review the combined role of anatomical and functional imaging in staging and follow-up of lymphoma, with particular attention to the role of CT in describing the cause of metabolic hyperactivity
- to describe the different CT patterns of lymphoma lung involvement and learn how CT can distinguish from infectious or drug related complications

Lymphoma

T. Hany, Zurich/CH

- to understand the technique especially FDG-PET/CT imaging
- to have basic knowledge of lymphoma therapy
- to know the indications of FDG-PET/CT in lymphoma
- to know the limitations of FDG-PET imaging in lymphoma

Colorectal cancer

R. Beets-Tan, Amsterdam/NL

- to understand the role of MRI for staging and restaging of rectal cancer
- to learn about the relevant MR imaging features and pitfalls in interpretation

Learning Objectives

INTRODUCTION TO HYBRID IMAGING IN ONCOLOGY

August 31 – September 1, 2017
Vienna/Austria

Colorectal cancer

M. Stokkel, Amsterdam/NL

- to learn about the role of FDG-PET/CT for distant staging and for the detection of recurrences during follow-up after surgery
- to understand the pitfalls of interpretation of FDG-PET/CT

Prostate cancer

H.-P. Schlemmer, Heidelberg/DE

- to understand the key clinical issues of prostate cancer management and the essential role of imaging
- to learn how multiparametric MRI should be performed and interpreted in a standardised manner according to international guidelines
- to appreciate the strengths of multiparametric MR and TRUS/MR fusion guided biopsy in the clinical context
- to become familiar with the complementary roles of MR and PET for tumour detection, staging and personalised therapy

Prostate cancer

M. Hartenbach, Vienna/AT

- to become familiar with the different PET-tracers for prostate cancer imaging
- to discuss the use of hybrid PET imaging in recurrent prostate cancer
- to learn the role of hybrid PET imaging in primary prostate cancer staging

Gynaecologic cancer

R. Forstner, Salzburg/AT

- to understand the value of CT and MRI in gynaecological cancer staging
- to learn the pitfalls and limitations of MRI and CT in assessing relapse
- to illustrate scenarios where combining MRI and PET is crucial for treatment planning

Gynaecologic cancer

A. Rockall, London/UK

- to understand the optimal role and the limitations of FDG-PET/CT in gynaecological cancer
- to know the pitfalls on PET imaging that can readily be avoided by joint review with MRI
- to know the key advantages of combining PET information with MRI
- to learn about new tracers being developed for use in gynaecologic cancer



Please note that programmes are marked with a logo to indicate their classification according to the European Training Curriculum.

LEVEL I First three years of training

LEVEL II Fourth and fifth year of training
(general radiologist standard)

LEVEL III Subspecialty training standard

ESOR stands for education in partnership.

This ASKLEPIOS Course is implemented with great support and partnership of ESHI (European Society of Hybrid Medical Imaging).

